Results 111 to 120 of about 27,657 (222)
A Functionally Conserved Enhancer is Critical for PGC1A Expression and Thermogenesis in Brown Fat
Advanced Science, Volume 13, Issue 31, 4 June 2026.An evolutionarily conserved enhancer controls PGC1A expression and thermogenic activation in brown adipose tissue. Integrative multi‐omics analyses identify two BAT‐specific enhancers, with PGC1A‐En1 functioning as the dominant regulatory element that maintains thermogenic capacity across species.
Duo Su +10 more
wiley +1 more source
Human Genomics, 2008 Polymorphisms in drug transporter genes and/or drug-metabolising enzyme genes may contribute to inter-individual variability in rosiglitazone pharmacokinetics in humans.
Aquilante Christina L +5 more
doaj +1 more source
Rosiglitazone reverses tenofovir-induced nephrotoxicity
, 2008 Tenofovir disoproxil fumarate (TDF) is a first-line drug used in patients with highly active retroviral disease; however, it can cause renal failure associated with many tubular anomalies that may be due to down regulation of a variety of ion ...
ANDRADE, Lucia +7 more
core +1 more source
Advanced Science, Volume 13, Issue 31, 4 June 2026.We demonstrate that Cars2, a cysteine catabolic enzyme in mouse iBAT, is critical for cold tolerance and brown adipocyte differentiation. Through its CPERS activity, Cars2 produces CysSSH/H2S to induce EBF2 persulfidation, promoting its interaction with PPARγ and BRG1 to enhance thermogenic gene expression.
Xin Peng +8 more
wiley +1 more source
Silymarin and Its Isolated Flavanonol Lignans Are Liver X Receptor Antagonists
Archiv der Pharmazie, Volume 359, Issue 6, June 2026.Despite its long tradition in the treatment of liver‐related ailments, the precise mode of action of the milk thistle fruit extract remains vague. Here we identified liver X receptor as a molecular target of silymarin, a mixture of bioactive compounds from milk thistle extract, and its major flavanonol lignan components, which account for their anti ...
Nils C. Bandomir +3 more
wiley +1 more source
SAGE Open Medicine, 2016 Background: Throughout 2007 and January 2008, several glitazones health warnings were published on rosiglitazone myocardial infarction risk. The impact of such warnings on glitazones prevalence of utilization has been extensively studied in the United ...
Eduardo Carracedo-Martínez +1 more
doaj +1 more source
Frontiers in Molecular Neuroscience, 2017 There is increasing interest in the association between depression and the development of metabolic diseases. Rosiglitazone, a therapeutic drug used to treat type 2 diabetes mellitus, has shown neuroprotective effects in patients with stroke and ...
Zhan Zhao +10 more
doaj +1 more source
Rosiglitazone transiently disturbs calcium homeostasis in monocytic cells
, 2008 The PPARγ agonist Rosiglitazone exerts anti-hyperglycaemic effects by regulating the long-term expression of genes involved in metabolism, differentiation and inflammation. In the present study, Rosiglitazone treatment rapidly inhibited (5–30 min) the ER
Atkin, L. +7 more
core +1 more source
Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.Figure 1 visually summarizes the core biological functions and therapeutic potential of the HGF/c‐Met signaling axis. Abstract Hepatocyte growth factor (HGF) is a multifunctional cytokine that activates the tyrosine kinase activity of its specific receptor, c‐Met (mesenchymal–epithelial transition factor).
Hongqin Sun +7 more
wiley +1 more source
Journal of Diabetes Research, 2018 Rosiglitazone is an agonist of peroxisome proliferator-activated receptor- (PPAR-) γ that is principally associated with insulin action. The exact mechanisms underlying its insulin-sensitizing action are still not fully elucidated.
Jia Li +6 more
doaj +1 more source